Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07342439 · ClinicalTrials.gov registry record · Phase 3
Study of Serine Supplementation to Protect Vision in MacTel
A Phase 3 study, sponsored by The Lowy Medical Research Institute Limited.
- Not yet
- Registry status
- Phase 3
- Development phase
- 120
- Enrollment target
NCT07342439: Clinical Trial Phase 3 study, sponsored by The Lowy Medical Research Institute Limited.
NCT07342439 is a Phase 3 study that has not yet begun recruiting, run by The Lowy Medical Research Institute Limited. The registered enrollment target is 120 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (84% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07342439, a Phase 3 study, has not yet begun recruiting, sponsored by The Lowy Medical Research Institute Limited.
- NOT YET RECRUITING
- Registry status
- Phase 3
- Development phase
- 120 participants
- Enrollment target
Study Summary
The goal of this clinical trial is to look at the efficacy and safety of giving oral serine (an amino acid) on the progression of structural and functional changes of the retina in people with MacTel type 2. The main questions it aims to answer are: * Does serine slow the progression of MacTel? * Is long-term serine supplementation safe in people with MacTel? Researchers will compare serine to a placebo (a look-alike substance that contains no drug) to see if serine works to slow the progression of MacTel. Participants will: * Take serine or a placebo twice a day for 24 months * Visit the clinic once every 6 months for eye exam, eye imaging and blood tests * Keep a diary of their symptoms, missed doses, and changes in medications
Primary Outcome
Mean rate of change in the total area of EZ loss (IS/OS; macular photoreceptor loss) from Baseline (BL) through Month 24 (M24), as assessed using SD-OCT in the study eye(s).
Interventions
- OTHER Placebo
- DRUG L-serine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2026-09 |
| Est. Completion | 2030-02 |
| Phase | Phase 3 |
What is known before NCT07342439 opens enrollment
NCT07342439 is an interventional study that assigns participants to a tested intervention. The registered 120 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (84% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT07342439 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07342439 about?
NCT07342439 is a clinical study titled "Study of Serine Supplementation to Protect Vision in MacTel". The goal of this clinical trial is to look at the efficacy and safety of giving oral serine (an amino acid) on the progression of structural and functional changes of the retina in people with MacTel type 2. The main questions it aims to answer are: * Does serine slow the progression of MacTel? * I...
What is the current status of trial NCT07342439?
This trial is currently not yet recruiting. It is a Phase 3 study. The enrollment target is 120 participants. The study started on 2026-09. Estimated completion is 2030-02.
What interventions are being tested in trial NCT07342439?
The interventions under investigation include: Placebo (OTHER), L-serine (DRUG).
Who is sponsoring clinical trial NCT07342439?
This trial is sponsored by The Lowy Medical Research Institute Limited, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07342439's enrollment target sits among peer trials
120 1619th of 2000 higher than 361 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01174108 · 120 participants · Phase 2
Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells
- NCT01627301 · 120 participants · NA
Sympathetic Overactivity in Post-traumatic Stress Disorder
- NCT02025023 · 120 participants · Phase 3
Local 5-Fluorouracil Injection for the Treatment of Chalazia: A Prospective, Comparative Study
- NCT02128906 · 120 participants · Phase 2
Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia